Correlation Between Zentalis Pharmaceuticals and Madrigal Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Zentalis Pharmaceuticals and Madrigal Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zentalis Pharmaceuticals and Madrigal Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Zentalis Pharmaceuticals Llc and Madrigal Pharmaceuticals, you can compare the effects of market volatilities on Zentalis Pharmaceuticals and Madrigal Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zentalis Pharmaceuticals with a short position of Madrigal Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zentalis Pharmaceuticals and Madrigal Pharmaceuticals.

Diversification Opportunities for Zentalis Pharmaceuticals and Madrigal Pharmaceuticals

0.34
  Correlation Coefficient

Weak diversification

The 3 months correlation between Zentalis and Madrigal is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding Zentalis Pharmaceuticals Llc and Madrigal Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Madrigal Pharmaceuticals and Zentalis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zentalis Pharmaceuticals Llc are associated (or correlated) with Madrigal Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Madrigal Pharmaceuticals has no effect on the direction of Zentalis Pharmaceuticals i.e., Zentalis Pharmaceuticals and Madrigal Pharmaceuticals go up and down completely randomly.

Pair Corralation between Zentalis Pharmaceuticals and Madrigal Pharmaceuticals

Given the investment horizon of 90 days Zentalis Pharmaceuticals is expected to generate 1.6 times less return on investment than Madrigal Pharmaceuticals. In addition to that, Zentalis Pharmaceuticals is 1.3 times more volatile than Madrigal Pharmaceuticals. It trades about 0.05 of its total potential returns per unit of risk. Madrigal Pharmaceuticals is currently generating about 0.1 per unit of volatility. If you would invest  24,180  in Madrigal Pharmaceuticals on September 13, 2024 and sell it today you would earn a total of  6,475  from holding Madrigal Pharmaceuticals or generate 26.78% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Zentalis Pharmaceuticals Llc  vs.  Madrigal Pharmaceuticals

 Performance 
       Timeline  
Zentalis Pharmaceuticals 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Zentalis Pharmaceuticals Llc are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite quite weak basic indicators, Zentalis Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point.
Madrigal Pharmaceuticals 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Madrigal Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite quite inconsistent technical and fundamental indicators, Madrigal Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point.

Zentalis Pharmaceuticals and Madrigal Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Zentalis Pharmaceuticals and Madrigal Pharmaceuticals

The main advantage of trading using opposite Zentalis Pharmaceuticals and Madrigal Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zentalis Pharmaceuticals position performs unexpectedly, Madrigal Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Madrigal Pharmaceuticals will offset losses from the drop in Madrigal Pharmaceuticals' long position.
The idea behind Zentalis Pharmaceuticals Llc and Madrigal Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Complementary Tools

Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities